Skip to main content
OpenTrials

Clinical trial condition

Immune System Diseases

Explore clinical trials studying Immune System Diseases. Study availability and eligibility vary by location and protocol.

35,780 public trials 5,051 recruiting studies
Refine in advanced search Browse all conditions

Immune System Diseases trial results

Recruiting

A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

NCT06634589

Conditions
B-cell Lymphoma, B-cell Malignancy, Disease Attributes, +15 more
Locations
  • Mayo Clinic Phoenix Phoenix, Arizona, United States
  • University of Southern California Norris Comprehensive Los Angeles, California, United States
  • Mayo Clinic Jacksonville Jacksonville, Florida, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View all 50 locations
View Trial Details
Recruiting

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

NCT05294731

Conditions
B-cell Malignancy, Blood Protein Disorders, Cardiovascular Diseases, +36 more
Locations
  • The First Affiliated Hospital of Bengbu Medical University Bengbu, Anhui, China
  • Anhui Provincial Hospital Hefei, Anhui, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Beijing Chao Yang Hospital,Capital Medical University Beijing, Beijing Municipality, China
View all 29 locations
View Trial Details
Recruiting

A Study of E6742 in Participants With Systemic Lupus Erythematosus

NCT07515014

Conditions
Autoimmune Diseases, Connective Tissue Diseases, Immune System Diseases, +3 more
Locations
  • The First Affiliated Hospital of Bengbu Medical University Bengbu, Anhui, China
  • Peking Union Medical College Hospital - East Campus Beijing, Beijing Municipality, China
  • Nanfang Hospital Southern Medical University - PPDS Guangzhou, Guangdong, China
  • The Third Affiliated Hospital, Sun Yat-Sen University Guangzhou, Guangdong, China
View all 54 locations
View Trial Details
Recruiting

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

NCT07101328

Conditions
B-cell Lymphoma, Blood Protein Disorders, Cardiovascular Diseases, +23 more
Locations
  • City of Hope Duarte, California, United States
  • University of Colorado Denver - School of Medicine - Anschutz Medical Campus Aurora, Colorado, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Yale University School of Medicine - Yale Cancer Center New Haven, Connecticut, United States
View all 51 locations
View Trial Details
Recruiting

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

NCT07294170

Conditions
AChR-Ab Seropositive Generalized Myasthenia Gravis, Autoimmune Diseases, Autoimmune Diseases of the Nervous System, +15 more
Locations
  • Profound Research LLC - Carlsbad Carlsbad, California, United States
  • Visionary Investigators Network Miami, Florida, United States
  • University of South Florida Tampa, Florida, United States
  • Henry Ford Health System Detroit, Michigan, United States
View all 30 locations
View Trial Details
Recruiting

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

NCT07284420

Conditions
AChR-Ab Seropositive Generalized Myasthenia Gravis, Autoimmune Diseases, Autoimmune Diseases of the Nervous System, +15 more
Locations
  • Profound Research LLC - Carlsbad Carlsbad, California, United States
  • Visionary Investigators Network Miami, Florida, United States
  • University of South Florida Tampa, Florida, United States
  • Henry Ford Health Systems Detroit, Michigan, United States
View all 27 locations
View Trial Details
Recruiting

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

NCT04728893

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Lymphocytic Leukaemia, +24 more
Locations
  • Highlands Oncology Group ( Site 2728) Springdale, Arkansas, United States
  • University of California San Diego Moores Cancer Center ( Site 2717) La Jolla, California, United States
  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site 2724) Torrance, California, United States
  • Colorado Blood Cancer Institute ( Site 2726) Denver, Colorado, United States
View all 121 locations
View Trial Details
Recruiting

Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).

NCT06751238

Conditions
Arthritis, Arthritis, Juvenile, Autoimmune Diseases, +7 more
Locations
  • University of Florida Gainesville, Florida, United States
  • Ann and Robert H Lurie Childs Hosp Chicago, Illinois, United States
  • Levine Childrens Hospital Charlotte, North Carolina, United States
  • Cincinnati Childrens Hospital Cincinnati, Ohio, United States
View Trial Details
Recruiting

Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

NCT05996627

Conditions
Bronchial Diseases, Bronchiolitis, Bronchiolitis Obliterans, +9 more
Locations
  • City of Hope Duarte, California, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View Trial Details

Related conditions